How should a patient on Mixtard (biphasic insulin aspart 30/70) 36 U in the morning and 24 U in the evening be switched to a weekly insulin icodec regimen, including initial and maintenance doses?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Mixtard 30/70 to Weekly Insulin Icodec

For a patient on Mixtard 36 units morning and 24 units evening (total 60 units/day), calculate the initial weekly icodec dose as 420 units (60 × 7), and for faster glycemic control, administer 630 units for the first week only (420 × 1.5, rounded to 630 units), then reduce to 420 units weekly from week 2 onwards. 1

Important Caveat: Mixtard is NOT Pure Basal Insulin

Critical consideration: Mixtard 30/70 is a biphasic insulin containing 30% rapid-acting and 70% intermediate-acting insulin—it is NOT a pure basal insulin. The guideline recommendations are specifically designed for switching from once-daily or twice-daily basal insulin only 1. When switching from Mixtard, you must account for the fact that approximately 30% of the total daily dose is providing prandial (mealtime) coverage.

Recommended Approach

Step 1: Calculate the Basal Component

  • Total daily Mixtard dose: 60 units (36 + 24)
  • Approximate basal component: 42 units/day (70% of 60 units)
  • The remaining 18 units (30%) was providing prandial coverage

Step 2: Initial Icodec Dosing Options

Option A - Conservative approach (recommended):

  • Calculate based on basal component only: 42 units × 7 = 294 units/week
  • With 50% loading dose for week 1: 294 × 1.5 = 441 units (round to 440 units)
  • From week 2 onwards: 294 units weekly (round to 290 units)
  • Add mealtime insulin (rapid-acting insulin aspart or lispro) to replace the lost prandial coverage, starting with approximately 4-6 units per main meal

Option B - If continuing without prandial insulin:

  • Use full Mixtard dose: 60 units × 7 = 420 units/week
  • With 50% loading dose for week 1: 420 × 1.5 = 630 units
  • From week 2 onwards: 420 units weekly
  • Monitor closely for postprandial hyperglycemia

Step 3: Loading Dose Decision

The 50% one-time additional dose for the first injection achieves steady state in 2-3 weeks versus 3-4 weeks without it 1. However, you may omit the loading dose if:

  • The patient frequently misses insulin doses (may overestimate actual insulin need) 1
  • The patient has hypoglycemia unawareness or history of severe hypoglycemia 1
  • The patient is elderly, has renal/hepatic impairment, or low body weight 1
  • The patient has preserved insulin sensitivity 1

Step 4: Monitoring and Titration

Monitoring requirements:

  • Measure prebreakfast self-measured blood glucose (SMBG) at least 3 times per week
  • Target range: 80-130 mg/dL (4.4-7.2 mmol/L) 1
  • Begin titration from week 2 (if no loading dose) or week 3 (if loading dose used) 1

Titration strategy:

  • Adjust by ±20 units weekly based on three prebreakfast SMBG values (2 days prior and day of next injection) 1
  • If any value is below target range, use the lowest value for titration decision
  • If all values are above target range, use the mean of three measurements 1
  • For high-risk patients (elderly, renal/hepatic impairment), consider more conservative titration in 10-unit increments 1

Critical Safety Warnings

Avoid dosing errors:

  • Do NOT continue the 50% loading dose beyond the first injection—this is the most common error and can cause severe hypoglycemia 1
  • Ensure patient understands the dose reduction from week 2 onwards
  • The icodec pen allows minimum adjustments of 10 units 1

Hypoglycemia risk:

  • Exercise caution in patients with hypoglycemia unawareness, recurrent severe hypoglycemia, or cardiovascular disease within 180 days 1
  • Rates of clinically significant hypoglycemia with icodec are generally comparable to daily basal insulins in type 2 diabetes 1

Special populations:

  • Asian patients: Consider lower starting doses (30-70 U/week per local labels) 1
  • Low BMI or chronic kidney disease: Consider starting at 50 U/week 1
  • High insulin resistance or elevated HbA1c: May require higher doses 1

The Prandial Coverage Gap

This is the most important clinical consideration: By switching from Mixtard to icodec alone, you are removing approximately 18 units/day of prandial insulin coverage. This will likely result in postprandial hyperglycemia unless you add mealtime rapid-acting insulin. The ONWARDS trials specifically studied switches from basal insulin only, not from premixed insulins 1.

Strongly consider: Adding rapid-acting insulin (aspart, lispro, or glulisine) with meals, starting with 4-6 units per main meal and titrating based on 2-hour postprandial glucose targets of <180 mg/dL (<10.0 mmol/L).

Related Questions

What is the recommended approach to initiating once‑weekly basal insulin (insulin icodec) in a patient with type 2 diabetes who requires basal insulin but prefers fewer injections?
What weekly dose of insulin icodec should be given to an adult with type 2 diabetes who is currently on insulin glargine 36 units per day?
How should Awiqli (insulin icodec) be initiated and titrated in an adult with type 1 or type 2 diabetes requiring basal insulin?
What is the appropriate dosing regimen for initiating weekly insulin icodec in an adult (≥18 years) with type 2 diabetes who is insulin‑naïve?
What is the maximum dose of basal insulin?
What weekly dose of insulin icodec should be given to an adult with type 2 diabetes who is currently on insulin glargine 36 units per day?
What is the recommended follow‑up schedule and management after adrenalectomy, including timing of visits, laboratory tests, and steroid replacement guidelines?
In a 67-year-old male with incidentally discovered hepatic lesions on CT urogram, do the lesions require further evaluation?
According to the latest American Heart Association guidelines, what is the recommended duration of targeted temperature management after return of spontaneous circulation following cardiac arrest?
Are polypoid lesions on the lateral bladder wall likely malignant or benign?
During CPR on a patient rescued from a pool after a diving injury who may have a cervical spine injury and is receiving bag‑mask ventilation, should I provide inline cervical immobilization and open the airway with a jaw‑thrust maneuver instead of a head‑tilt‑chin‑lift?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.